News

ConvaTec announces the appointment of Ken Berger to the position of CEO effective March 6, 2012

ConvaTec announces the appointment of Ken Berger to the position of CEO effective March 6, 2012

February 21 2012

David I. Johnson to step down as CEO and resign from
Board of Directors

ConvaTec, a world-leading developer and marketer of
innovative medical technologies for community and hospital care,
today announces that Ken Berger will assume the position of CEO,
ConvaTec, and will be appointed to the ConvaTec Board of
Directors.

Berger joins ConvaTec from Thermo Fisher Scientific where he
spent the last ten years, most recently as Senior Vice President
and Group resident of the Specialty Diagnostics Group, a global $2
billion high-value diagnostics business. "We are excited to
have Ken take over the helm of ConvaTec," said Toni Weitzberg,
Chairman of the Board of Directors for ConvaTec. "His track
record of building highly profitable businesses, combined with
diverse global experience and a history of building strong
leadership teams is well suited to take ConvaTec to the next level
of performance excellence."

"I am pleased to work with Nordic Capital and Avista Capital
Partners as CEO of ConvaTec," said Berger, "and I look forward to
working with the ConvaTec team to realize the incredible potential
of this business."

This appointment follows the mutual agreement between David I.
Johnson and the ConvaTec Board of Directors that he will step down
as CEO, effective March 5, 2012. "Dave successfully managed
the carve-out from Bristol Myers Squibb Co. and created an
independent global company with a strong platform for growth."
stated Weitzberg, "The Board thanks him for his service in leading
ConvaTec over the past six years, and for his dedication to the
Company for over twelve years."

"I am proud to leave this fine organization with a strengthened
financial foundation, renewed growth momentum; and of course, a
continued commitment to the company mission." said Johnson.
"I am confident that the entire organization is ready to take
ConvaTec to even greater heights."

Over the next sixty days, Johnson will work with the Board and
his successor to ensure an orderly transition of leadership.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative
medical technologies that have helped improve the lives of millions
of people worldwide. With four key focus areas - Ostomy Care, Wound
Therapeutics, Continence and Critical Care, and Infusion Devices -
ConvaTec products support healthcare professionals from the
hospital to the community health setting. For more information,
please visit www.convatec.com.